Anxiety Disorders Completed Phase 2 Trials for MK-0777 (DB12238)

Also known as: Anxiety Disorder / Anxiety NOS

IndicationStatusPhase
DBCOND0027904 (Anxiety Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00543920A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)Treatment
NCT00546624GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)Treatment